Acumen Pharma's ACU193 Shows Potential in Alzheimer's Trial; Bullish View for EnerSys
- July 16th, 2023
- 414 views
Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) announced positive topline results from the Phase 1 INTERCEPT-AD trial evaluating the company's ACU193, a clinical-stage antibody therapy targeting amyloid beta oligomers (AβOs) in early Alzheimer's disease (AD).
The trial met primary and secondary objectives, demonstrating proof-of-mechanism for ACU193. Remarkably, higher dose cohorts showed rapid and significant amyloid plaque reduction, paving the way for potential monthly dosing.
On Friday, $ABOS closed at $6.28, reflecting an increase of $0.16 (+2.61%).
In other news, EnerSys (NYSE: ENS), a leading provider of stored energy solutions for industrial applications, received coverage initiation from CL King with a Buy rating and a price target of $137.
Considering $ENS closed at $110.68 on Friday, the suggested price target suggests a potential upside of $26.32 or approximately 23.77%, according to the investment firm's view.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026The Work Behind the Game: How Football Teams Prepare to Compete
September 15th, 2026NJCP Operates on a Prep Model Built Around a Full Season
September 14th, 2026Earnings Preview: High Tide, Kestra Medical, and RF Industries in Focus
September 12th, 2026
Member Login